Investors & Media

Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

Phase 2 open-label study data reinforce donidalorsen’s potential to be a best-in-class prophylactic treatment for patients living with hereditary angioedema Ionis is preparing to launch donidalorsen, one of its three near-term commercial opportunities CARLSBAD, Calif. , Feb.

Read more
You are now leaving to visit